Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Location
175 Innovation Boulevard, Wilmington, DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 532 % -50.6%
Debt-to-equity 34.7 % +116%
Return On Equity -107 % -78.1%
Return On Assets -79.1 % -53.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.6M shares +2.86%
Entity Public Float 66.1M USD -14.3%
Weighted Average Number of Shares Outstanding, Basic 76M shares +0.31%
Weighted Average Number of Shares Outstanding, Diluted 76M shares +0.31%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3M USD
Research and Development Expense 116M USD +1.91%
General and Administrative Expense 26.3M USD -8.45%
Operating Income (Loss) -135M USD +5.11%
Net Income (Loss) Attributable to Parent -124M USD +4.26%
Earnings Per Share, Basic -1 USD/shares +8.43%
Earnings Per Share, Diluted -1 USD/shares +8.43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.8M USD -7.46%
Marketable Securities, Current 47.5M USD -68.8%
Assets, Current 76.9M USD -57.9%
Property, Plant and Equipment, Net 5.96M USD -21.2%
Operating Lease, Right-of-Use Asset 27.9M USD -5.55%
Assets 115M USD -48.8%
Accounts Payable, Current 4.96M USD -19.6%
Employee-related Liabilities, Current 5.88M USD +4.33%
Accrued Liabilities, Current 13.2M USD +15.8%
Liabilities, Current 20.9M USD -10.4%
Operating Lease, Liability, Noncurrent 15.2M USD -1.68%
Other Liabilities, Noncurrent 2.97M USD -7.75%
Liabilities 39.1M USD -6.99%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +99.7%
Retained Earnings (Accumulated Deficit) -647M USD -23.8%
Stockholders' Equity Attributable to Parent 75.8M USD -58.4%
Liabilities and Equity 115M USD -48.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.2M USD -7.68%
Net Cash Provided by (Used in) Financing Activities -160K USD
Net Cash Provided by (Used in) Investing Activities 62.2M USD +99.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 27.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.8M USD -6.51%
Deferred Tax Assets, Valuation Allowance 183M USD +23.7%
Deferred Tax Assets, Gross 188M USD +23%
Operating Lease, Liability 17.9M USD +1.24%
Payments to Acquire Property, Plant, and Equipment 47K USD -83.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -124M USD +4.18%
Lessee, Operating Lease, Liability, to be Paid 40.2M USD -5.86%
Property, Plant and Equipment, Gross 12M USD +10.4%
Operating Lease, Liability, Current 2.71M USD +21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.05M USD +2.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.97M USD +8.27%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22.3M USD -10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.12M USD +2.29%
Deferred Tax Assets, Operating Loss Carryforwards 81.5M USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.2M USD +2.3%
Operating Lease, Payments 620K USD
Depreciation, Depletion and Amortization 435K USD +2.11%
Deferred Tax Assets, Net of Valuation Allowance 5.02M USD +0.04%
Share-based Payment Arrangement, Expense 17.3M USD -28.5%